Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 16/20 | 0.99 |
| ▸ | BCR known ✓ | P11274 | 8/20 | 0.99 |
| ▸ | KIT | P10721 | 11/20 | 0.99 |
| ▸ | LDLR | P01130 | 8/20 | 0.99 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 0.99 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.99 |
| ▸ | LCK | P06239 | 4/20 | 0.99 |
| ▸ | LYN | P07948 | 4/20 | 0.99 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.99 |
| ▸ | FLT3 | P36888 | 4/20 | 0.99 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.99 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.99 |
| ▸ | SRC | P12931 | 2/20 | 0.99 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.99 |
| ▸ | CA12 | O43570 | 1/20 | 0.99 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.99 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.99 |
| ▸ | STK10 | O94804 | 1/20 | 0.99 |
| ▸ | CA1 | P00915 | 1/20 | 0.99 |
| ▸ | CA2 | P00918 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilotinib SCHEMBL26181009 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28663798 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL2223849 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL29693815 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL30715492 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL29392981 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL235245 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL18095566 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1460791 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL30715493 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181128-B1 | NILOTINIB PHARMACEUTICALCOMPOSITION | XSPRAY PHARMA AB PUBL (SE) | 2023-03-08 | — | — | EP | claimed |
| EP-3766486-A1 | A METHOD FOR PRODUCING STABLE, AMORPHOUS HYBRID NANOPARTICLES OF AT LEAST ONE PROTEIN KINASE INHIBITOR AND AT LEAST ONE POLYMERIC STABILIZING AND MATRIX-FORMING COMPONENT | XSpray Microparticles AB (SE) | 2021-01-20 | — | — | EP | claimed |
| US-10772877-B2 | Pharmaceutical compositions | XSPRAY MICROPARTICLES AB (SE) | 2020-09-15 | — | — | US | claimed |
| US-20200253941-A1 | PHARMACEUTICAL COMPOSITIONS | XSPRAY MICROPARTICLES AB (SE) | 2020-08-13 | — | — | US | claimed |
| US-10314830-B2 | Pharmaceutical compositions | XSPRAY MICROPARTICLES AB (SE) | 2019-06-11 | — | — | US | claimed |
| US-9833442-B2 | Pharmaceutical compositions | XSPRAY MICROPARTICLES AB (SE) | 2017-12-05 | — | — | US | claimed |
| US-20170143715-A1 | PHARMACEUTICAL COMPOSITIONS | XSPRAY MICROPARTICLES AB (SE) | 2017-05-25 | — | — | US | claimed |
| EP-2068839-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB OR ITS SALT | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | claimed |
| EP-1910336-B1 | MONOHYDROCHLORIDE MONOHYDRATE SALT OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE | NOVARTIS AG (CH) | 2011-06-29 | — | — | EP | claimed |
| US-20250375449-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | XSPRAY PHARMA AB (SE) | 2025-12-11 | — | — | US | disclosed |
| US-12419892-B2 | Pharmaceutical compositions comprising nilotinib | XSPRAY PHARMA AB (SE) | 2025-09-23 | — | — | US | disclosed |
| WO-2025099249-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | XSPRAY PHARMA AB (SE) | 2025-05-15 | — | — | WO | disclosed |
| US-20250144096-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | XSPRAY PHARMA AB (SE) | 2025-05-08 | — | — | US | disclosed |
| EP-4260848-A1 | PHARMACEUTICAL COMPOSITION FOR SOLID DOSAGE FORM CONTAINING NILOTINIB AND PROCESS FOR ITS PREPARATION | Lotus Pharmaceutical Co., Ltd. (TW) | 2023-10-18 | — | — | EP | disclosed |
| EP-3181128-B1 | NILOTINIB PHARMACEUTICALCOMPOSITION | XSPRAY PHARMA AB PUBL (SE) | 2023-03-08 | — | — | EP | disclosed |
| EP-3189045-B1 | NOVEL SALTS OF NILOTINIB AND POLYMORPHS THEREOF | SUN PHARMACEUTICAL IND LTD (IN) | 2022-02-09 | — | — | EP | disclosed |
| EP-3271351-A1 | NOVEL POLYMORPHIC FORM X OF NILOTINIB DIHYDROCHLORIDE HYDRATE | Cipla Limited (IN) | 2018-01-24 | — | — | EP | disclosed |
| WO-2017064538-A1 | PHARMACEUTICAL COMPOSITIONS OF NILOTINIB HYDROCHLORIDE | NOBEL ILAC SANAYII VE TICARET A.S. (TR) | 2017-04-20 | — | — | WO | disclosed |
| WO-2016151304-A1 | NOVEL POLYMORPHIC FORM X OF NILOTINIB DIHYDROCHLORIDE HYDRATE | CIPLA LIMITED (IN) | 2016-09-29 | — | — | WO | disclosed |
| WO-2011086541-A1 | NOVEL POLYMORPH OF NILOTINIB MONOHYDROCHLORIDE MONOHYDRATE | GENERICS [UK] LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |